One-glance verdict
Not enough data
Fair value unavailable
Not enough cash-flow history to value this one with our method.
Fundamentals snapshot
Abeona Therapeutics Inc.
ABEO · NCM · Healthcare · Biotechnology
Current price
$2.54
52-week range
$2.30 - $7.65
Market cap
$156.62M
Balance sheet
Healthy
-23.92x Concerning
Net cash $126.95M. Interest coverage shows how many times profit covers the interest bill.
What stands out
1 Reward
0 Risks
1 rewards · 0 risks
View details ↓What this company does
Abeona Therapeutics Inc.
Abeona Therapeutics develops gene and cell therapies, which are like highly specialized medicines, to treat rare and serious genetic diseases. Their main money comes from selling these experimental treatments as they get approved, and this matters because it shows if their groundbreaking science can actually help patients and be a successful business.
How the company got here
Abeona Therapeutics Inc. was founded in 1974 and has evolved significantly over the years, formerly known as PlasmaTech Biopharmaceuticals, Inc. before changing its name in June 2015. The company's journey has been marked by a strategic shift towards developing advanced cell and gene therapies for rare and life-threatening genetic diseases. This focus has led to the development of its proprietary AIM™ vector platform, which is designed to improve the targeted delivery of genetic therapies to specific tissues. Abeona's commitment to innovation in this specialized field has positioned it as a key player in the biopharmaceutical industry.
What it actually does
Abeona Therapeutics is a biopharmaceutical company that focuses on creating cutting-edge cell and gene therapies. These therapies aim to treat serious and often life-threatening genetic diseases. Think of it like this: instead of a traditional pill, Abeona develops treatments that work by modifying a patient's own cells or by delivering specific genes to correct underlying genetic defects. Their work is highly specialized, targeting rare conditions where there are currently limited or no effective treatment options.
ZEVASKYN (prademagene zamikeracel)
ZEVASKYN is Abeona's first approved product, a type of therapy called an autologous cell-based gene therapy. It's designed to treat wounds in patients with a severe skin condition called recessive dystrophic epidermolysis bullosa (RDEB). RDEB is a genetic disorder that makes the skin extremely fragile and prone to blistering and open wounds. ZEVASKYN works by using a patient's own skin cells, which are genetically modified in a lab to produce a crucial protein (type VII collagen) that helps the skin heal and stay intact. This therapy is manufactured in Abeona's specialized facility in Cleveland, Ohio, and was approved by the FDA in April 2025.
Ophthalmology Programs (ABO-503, ABO-504, ABO-505)
Abeona is developing a portfolio of gene therapies aimed at treating various inherited eye diseases. These include ABO-503 for X-linked retinoschisis (XLRS), a condition causing vision loss due to retinal cell damage; ABO-504 for Stargardt disease, which leads to progressive vision loss from photoreceptor cell death; and ABO-505 for autosomal dominant optic atrophy (ADOA), a disease affecting the optic nerve and leading to vision impairment. These therapies utilize Abeona's AIM™ vector platform, which is designed to deliver therapeutic genes effectively to the eye.
AIM Vector Platform
The AIM™ (Adeno-Associated Virus) vector platform is a core technology for Abeona, acting as a delivery system for their gene therapies. Think of it as a specialized vehicle designed to carry genetic material directly to the cells that need it. This platform is built using novel AAV capsids (the outer shell of the virus used in gene therapy) that are engineered for increased efficiency and tissue specificity. This means the AIM™ platform can potentially target specific organs like the brain, lungs, or eyes more effectively and may help evade immune responses that can occur with other gene therapy vectors.
What management is betting on now
Abeona's primary focus is on the commercialization and expansion of ZEVASKYN, its recently approved gene therapy for RDEB. Management is working to build out a network of specialized treatment centers and patient support programs to ensure broad access to the therapy. Simultaneously, the company is advancing its pipeline of gene therapies for ophthalmic diseases, leveraging its AIM™ vector platform. They are also exploring new therapeutic areas, such as engineered T-cell therapies for solid tumors, indicating a strategy to diversify its product offerings and address a wider range of serious diseases.
Price history
How the share price has moved
—
Loading price history…
Earnings history
Last 8 quarters — what happened
Click any quarter to read the call summary and what the numbers say.
FY2024 Q4
$-17.16M
FY2025 Q1
$-19.80M
FY2025 Q2
$-21.68M
FY2025 Q3
$-23.71M
FY2025 Q4
$-19.11M
FY2026 Q1
$-20.74M
FY2026 Q2
$-17.98M
FY2026 Q3
$-8.53M
Revenue
$13.49M
Net income
$-4.81M
Diluted EPS
-0.08
Operating cash flow
$-8.31M
Free cash flow
$-8.53M
Fetching…
Sources
Revenue
$11.38M
Net income
$-20.19M
Diluted EPS
-0.35
Operating cash flow
$-17.50M
Free cash flow
$-17.98M
Fetching…
Sources
Revenue
$8.72M
Net income
$-17.07M
Diluted EPS
-0.30
Operating cash flow
$-19.80M
Free cash flow
$-20.74M
Fetching…
Sources
Revenue
$5.42M
Net income
$-20.46M
Diluted EPS
-0.36
Operating cash flow
$-17.95M
Free cash flow
$-19.11M
Fetching…
Sources
Revenue
$400.00K
Net income
$-5.16M
Diluted EPS
-0.10
Operating cash flow
$-21.19M
Free cash flow
$-23.71M
Fetching…
Sources
Revenue
$400.00K
Net income
$108.83M
Diluted EPS
1.71
Operating cash flow
$-18.78M
Free cash flow
$-21.68M
Fetching…
Sources
Revenue
—
Net income
$-12.03M
Diluted EPS
-0.24
Operating cash flow
$-18.40M
Free cash flow
$-19.80M
Fetching…
Sources
Revenue
—
Net income
$-9.29M
Diluted EPS
0.50
Operating cash flow
$-16.56M
Free cash flow
$-17.16M
Fetching…
Sources
Is it cheap or expensive?
Fair value — vs current price $2.54
We couldn't calculate a fair value right now.
Is it drowning in debt?
Healthy
Net cash $127.0M - more cash than debt. Interest coverage -23.9x.
Net debt
$-126.95M
Interest coverage
-23.92x
Abeona Therapeutics Inc.'s profit covers its interest bill about 0.0 times over. which is weaker than most peers shown here and 2 peers sit below 1x, which is the danger zone where profit does not fully cover the interest bill.
Healthy
Worse cushion
Baseline
Better cushion
ABEO
BASELINE
Abeona Therapeutics Inc.
Total debt $19.87M Interest coverage -23.92x This is the baseline the peer rows are being compared against.
Total debt $112.32M Interest coverage -8.69x Neither company has much profit cushion over interest right now.
Total debt $252.22M Interest coverage -3.58x Neither company has much profit cushion over interest right now.
What you should know
The case for and against ABEO
1 Reward
0 Risks
Rewards
-
Revenue grew 570.3% last year.
Risks
The numbers
All the key metrics, grouped by purpose
Tap any ? icon to learn what it means.
Valuation
How expensive the stock looks
P/E (TTM)
—
Forward P/E
-9.68x
P/B
1.13x
P/S
4.01x
EV/EBITDA
-0.26x
PEG ratio
—
Profitability
How much profit each dollar creates
Gross margin
-3.5%
Operating margin
-96.4%
Net margin
-160.3%
ROE
—
ROA
—
Health
Liquidity and balance-sheet strength
Debt / equity
0.16x
Current ratio
—
Quick ratio
—
Total debt
$19.87M
Total cash
$146.83M
Growth
How the business has been compounding
Revenue TTM
$39.01M
Revenue 5Y CAGR
18.0%
EPS TTM
-1.16
EPS 5Y CAGR
—
Cash flow
How much cash the business throws off
Operating CF TTM
$-63.56M
Free CF TTM
$-84.30M
FCF margin
-216.1%
Dividend
Shareholder payout
Yield
0.0%
Payout ratio
0.0%
Last ex-div date
—